|Other Names||Interleukin-12 subunit beta, IL-12B, Cytotoxic lymphocyte maturation factor 40 kDa subunit, CLMF p40, IL-12 subunit p40, NK cell stimulatory factor chain 2, NKSF2, IL12B, NKSF2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine- activated killer cells, and stimulate the production of IFN-gamma by resting PBMC.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL12B is a subunit of interleukin 12, a cytokinethat acts on T and natural killer cells, and has a broad array ofbiological activities. Interleukin 12 is a disulfide-linkedheterodimer composed of the 40 kD cytokine receptor like subunitencoded by this gene, and a 35 kD subunit encoded by IL12A. Thiscytokine is expressed by activated macrophages that serve as anessential inducer of Th1 cells development. This cytokine has beenfound to be important for sustaining a sufficient number ofmemory/effector Th1 cells to mediate long-term protection to anintracellular pathogen. Overexpression of this gene was observed inthe central nervous system of patients with multiple sclerosis(MS), suggesting a role of this cytokine in the pathogenesis of thedisease. The promoter polymorphism of this gene has been reportedto be associated with the severity of atopic and non-atopic asthmain children.
Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Miteva, L.D., et al. Rheumatol. Int. (2010) In press :de Heens, G.L., et al. J. Clin. Periodontol. 37(2):129-136(2010)Sobti, R.C., et al. Folia Biol. (Praha) 56(3):110-115(2010)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.